The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NUVB | +61.11% | -54.47% | -14.56% | -51% |
| S&P | +12.65% | +91.73% | +13.89% | +93% |
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
The bulls are lining up on Wall Street for this up-and-coming biotech stock.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.12M | 1704.7% |
| Gross Profit | $9.24M | 1072.3% |
| Gross Margin | 70.40% | 201.1% |
| Market Cap | $1.27B | 65.7% |
| Market Cap / Employee | $4.36M | 0.0% |
| Employees | 291 | 0.0% |
| Net Income | -$55.79M | -35.4% |
| EBITDA | -$55.90M | -16.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $98.90M | 229.3% |
| Accounts Receivable | $8.32M | 7331.3% |
| Inventory | 5.7 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $194.68M | 19664.5% |
| Short Term Debt | $13.47M | 32.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -37.08% | 51.5% |
| Return On Invested Capital | -36.30% | -21.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$52.90M | -69.4% |
| Operating Free Cash Flow | -$52.89M | -70.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.78 | 1.28 | 1.58 | 3.35 | 51.43% |
| Price to Sales | 113.84 | 54.39 | 46.29 | 47.36 | -83.65% |
| Price to Tangible Book Value | 1.79 | 1.29 | 1.60 | 3.46 | 54.74% |
| Enterprise Value to EBITDA | -7.49 | -2.48 | -4.11 | -16.56 | 797.07% |
| Return on Equity | -106.3% | -119.7% | -64.4% | -52.5% | -45.05% |
| Total Debt | $8.92M | $11.41M | $203.37M | $208.15M | 1759.82% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
